Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study.
Sato S, Uehara T, Toyoda K, Yasui N, Hata T, Ueda T, Okada Y, Toyota A, Hasegawa Y, Naritomi H, Minematsu K; Stroke Unit Multicenter Observational (SUMO) Study Group. Sato S, et al. Stroke. 2009 Jan;40(1):30-4. doi: 10.1161/STROKEAHA.108.524942. Epub 2008 Oct 23. Stroke. 2009. PMID: 18948604
Nationwide survey of antihypertensive treatment for acute intracerebral hemorrhage in Japan.
Koga M, Toyoda K, Naganuma M, Kario K, Nakagawara J, Furui E, Shiokawa Y, Hasegawa Y, Okuda S, Yamagami H, Kimura K, Okada Y, Minematsu K; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) Study Investigators. Koga M, et al. Among authors: yamagami h. Hypertens Res. 2009 Sep;32(9):759-64. doi: 10.1038/hr.2009.93. Epub 2009 Jun 26. Hypertens Res. 2009. PMID: 19557007
Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register.
Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Toyoda K, et al. Among authors: yamagami h. Stroke. 2009 Nov;40(11):3591-5. doi: 10.1161/STROKEAHA.109.562991. Epub 2009 Sep 17. Stroke. 2009. PMID: 19762694
Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry.
Naganuma M, Koga M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K, Toyoda K. Naganuma M, et al. Among authors: yamagami h. Cerebrovasc Dis. 2011;31(2):123-9. doi: 10.1159/000321516. Epub 2010 Nov 17. Cerebrovasc Dis. 2011. PMID: 21088392 Free article.
CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry.
Koga M, Kimura K, Shibazaki K, Shiokawa Y, Nakagawara J, Furui E, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Naganuma M, Nezu T, Maeda K, Minematsu K, Toyoda K. Koga M, et al. Among authors: yamagami h. J Neurol Sci. 2011 Jul 15;306(1-2):49-53. doi: 10.1016/j.jns.2011.03.046. Epub 2011 Apr 14. J Neurol Sci. 2011. PMID: 21492878
Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry.
Nezu T, Koga M, Nakagawara J, Shiokawa Y, Yamagami H, Furui E, Kimura K, Hasegawa Y, Okada Y, Okuda S, Kario K, Naganuma M, Maeda K, Minematsu K, Toyoda K. Nezu T, et al. Among authors: yamagami h. Stroke. 2011 Aug;42(8):2196-200. doi: 10.1161/STROKEAHA.111.614404. Epub 2011 Jun 30. Stroke. 2011. PMID: 21719764
625 results